Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas

The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the PAM axis with synergistic potential. This multice...

Full description

Bibliographic Details

Published in:	Haematologica
Main Authors:	Ajay Major, Justin Kline, Theodore G. Karrison, Paul A. S. Fishkin, Amy S. Kimball, Adam M. Petrich, Sreenivasa Nattam, Krishna Rao, Bethany G. Sleckman, Kenneth Cohen, Koen van Besien, Aaron P. Rapoport, Sonali M. Smith
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2021-07-01
Online Access:	https://haematologica.org/article/view/10347